(±)-Epinephrine (+) bitartrate, often called epinephrine bitartrate, enters the world as a key compound for pharmaceutical applications. The salt form improves the solubility of the parent epinephrine for use in injectable medications, most noticeably for allergic reactions and cardiac emergencies. Its use supports procedures in hospitals and ambulances where immediate response makes a difference between life and death. Researchers and medical professionals value this compound because it delivers a rapid physiological effect, increasing heart rate, constricting blood vessels, and easing the symptoms of anaphylaxis and asthma. The form matters: epinephrine as a free base doesn't mix well with water, but the bitartrate salt gives it the water-friendly property pharmaceuticals demand.
Examining the characteristics, (±)-epinephrine (+) bitartrate commonly appears as a white to off-white crystalline solid. Depending on conditions like humidity, you may find it as fine powder, granules, or small flakes. The texture allows manufacturers to measure it accurately for pharmaceuticals or laboratory setups. Its density reaches roughly 1.60 g/cm³, a factor critical for precise dosing in ampoules or vials. Neither sticky nor oily, the solid dissolves freely in water but shows lower solubility in organic solvents. This hydrophilic nature owes much to the tartrate component. Many in the lab appreciate that it stores well in cool, dry environments, preserving its activity for long periods as a shelf-stable solid.
The chemical structure blends the well-known epinephrine molecule, which itself belongs to the catecholamine family, with bitartrate. The molecular formula for (±)-epinephrine (+) bitartrate reads as C9H13NO3·C4H6O6 and the molar mass clocks in around 333.3 g/mol. This salt pairs one molecule of epinephrine with one of bitartrate. The three hydroxyl groups confer polarity, enabling the salt to dissolve in polar solvents like water. The molecule holds together tightly under ambient conditions. When analyzed using infrared or NMR spectroscopy, the fingerprints match those of epinephrine with the tartaric acid partner visible in its unique peaks.
Industry often specifies (±)-epinephrine (+) bitartrate with standards that cover purity (commonly above 98%), moisture content, content of active epinephrine, and the presence of residual solvents or related substances. Impurity control matters since contaminants in such a potent drug can create safety risks for patients. Bulk suppliers list its HS Code as 2922.50, which identifies it legally for customs and international trade. Preparation for injection means dissolving the powder in sterile water; the solution is clear, colorless, and stable when stored properly. Medical-grade packages often include specifications for particle size to support rapid dissolution and uniformity.
Handling (±)-epinephrine (+) bitartrate requires respect for its potency. Direct contact can cause irritation; airborne powder in a poorly ventilated lab poses inhalation risks to sensitive individuals. Accidental exposure can lead to heart palpitations, headache, or increases in blood pressure. Storage occurs in tightly sealed containers, away from light, at low temperatures to protect the active ingredient from degradation. Laboratories and factories use goggles, gloves, and local ventilation when measuring or transferring the powder. Spills involve prompt cleanup with absorbent material while avoiding static discharge that might stir fine dust. For workers, knowledge about emergency procedures, including medical response for accidental overdose, matters more than just routine training. The compound itself poses challenges for waste disposal, requiring neutralization before discarding residues down the drain or in landfill.
Production of (±)-epinephrine (+) bitartrate starts with the synthesis of racemic (±)-epinephrine, made through organic reactions that introduce the amine and catechol functional groups onto a benzene backbone. Pharmaceutical manufacturers source their raw chemical inputs, including precursor chemicals and tartaric acid, from vetted suppliers for regulatory compliance. Factories follow protocols under current Good Manufacturing Practices (cGMP) to exclude cross-contamination and guarantee consistent potency from batch to batch. Analytical techniques such as chromatography confirm the absence of unwanted enantiomers, degradants, or foreign compounds. Regulatory agencies oversee these steps, with documentation supporting traceability from raw input to finished injectable product.
Making highly pure (±)-epinephrine (+) bitartrate isn't just a matter of following recipes. Sophisticated equipment—like air-controlled rooms, high-performance liquid chromatography, and automated reactors—cut down risk of contamination and human error. The industry as a whole recognizes the danger posed by supply chain disruptions and quality lapses. Some producers work with local partners and global logistics teams to keep deliveries timely and safe. Investing in quality control, transparent documentation, and third-party certification reduces the risk of counterfeit or sub-potent material entering pharmacies or hospitals. Open channels between manufacturers, regulators, and end users make it easier to catch emerging issues and fix them before they affect real people. Organizations invest in continuous training for staff to ensure proper practices and conduct regular audits.
As emergency medicine and research evolve, (±)-epinephrine (+) bitartrate stands out as a key ingredient in life-saving interventions. Demand trends upward thanks to growing awareness of anaphylactic risk and increases in diagnostic lab capacity. Some forward-thinking companies explore newer formulations—like prefilled syringes or auto-injectors that extend shelf life and work reliably in field conditions. While epinephrine bitartrate has a strong safety record, secondary research tracks how even trace byproducts could challenge patient safety. There’s movement toward greening the production process, reducing environmental waste, and recycling solvents or unused intermediates. Community engagement, patient advocacy, and strong collaboration help build trust and transparency in every step from raw material to the pharmacy shelf.
Experience in both the lab and clinical settings confirms the impact of details—purity, stability, handling—on safety and quality. Each background fact, from molecular structure to density and hazard management, points to real consequences in how the final medication performs during emergencies. Staying vigilant about standards and changes in technology will help ensure (±)-epinephrine (+) bitartrate fulfills its role—not just as a chemical, but as a trusted ally in critical medical situations.
Providing high-quality chemical products and logistics solutions for global trade partners.
